## CORPORATE GOVERNANCE REFORMS

- A. <u>Review of Disclosures Giving Rise to the Litigation</u>: AdaptHealth's Audit Committee will retain outside counsel to conduct a postmortem review of the disclosures that gave rise to the Derivative Action as part of a concerted effort to improve the Company's governance practices. All work performed by retained outside counsel, including the results of its review and related reports to the Audit Committee, shall remain confidential and privileged.
- B. <u>Board Self-Evaluation</u>: AdaptHealth will be required to conduct mandatory evaluations that test the effectiveness of the Board of Director's governance and oversight procedures through the use of director questionnaires prepared by the Nominating and Governance Committee with the assistance of outside counsel, which shall consider industry guidance and best practices. Such questionnaires shall be distributed and completed once every three years. The Nominating and Governance Committee will review the results and report to the Board regarding the results and any recommendations for improvements.

## C. Board Composition and Practices:

- 1. AdaptHealth shall nominate and appoint, at its sole discretion, one (1) additional outside director to the Company's Board of Directors who meets the independence standards promulgated by NASDAQ.
- 2. The Nominating and Governance Committee shall annually evaluate the composition of the Board to: (a) assess the skills and expertise that are currently represented on the Board as a whole, and in individual directors, as well as the skills and experience that the Board may find valuable in the future; and (b) assess the effectiveness of the efforts to seek a diversity of occupational and personal backgrounds on the Board in order to obtain a range of viewpoints and perspectives and to enhance the diversity of the Board.
- D. Enhanced Board Reporting: The General Counsel, Chief Compliance Officer, Chief Accounting Officer or any independent member of the Board will be authorized to convene a meeting of the Audit Committee of the Board to review (1) any concerns, including whistleblower issues, reports of management wrongdoing, pending or threatened litigation, and such other matters that the General Counsel, Chief Compliance Officer, Chief Accounting Officer, or independent Board members identify and/or (2) any concerns, including any material compliance issues raised by the U.S. Securities and Exchange Commission ("SEC"), U.S. Department of Justice, or other regulatory agencies, and the effectiveness of AdaptHealth's policies, procedures, systems, and controls designed to ensure regulatory compliance.
- E. Enhanced Responsibilities of the Audit Committee:
  - 1. The Audit Committee will be required to consult the General Counsel, Chief Compliance Officer, and/or any other senior-level management representative, as it deems necessary, to review the accuracy of public disclosures with respect to

material investigations involving AdaptHealth's officers and directors that are required to be disclosed under state and/or federal laws and regulations.

- F. Enhanced Responsibilities of the Compliance Committee:
  - 1. The Compliance Committee will be required to consult the General Counsel, Chief Compliance Officer, and/or any other senior-level management representative, as it deems necessary, to review the accuracy of public disclosures with respect to (a) healthcare regulatory compliance matters that may have a material impact on AdaptHealth's operational performance or financial health and (b) material healthcare regulatory investigations involving AdaptHealth's officers and directors that are required to be disclosed under state and/or federal laws and regulations.
  - 2. The Compliance Committee will be required to meet with the Chief Compliance Officer at least twice a year.
- G. Enhanced Responsibilities of Management-Level Disclosure Committee:
  - 1. The Management-Level Disclosure Committee will report quarterly to the Audit Committee regarding the Disclosure Committee's meetings and activities.
  - 2. The Management-Level Disclosure Committee will be required to obtain approval from the CEO or CFO to implement any changes to its Charter.